25
Jun

Close to a year ago Switzerland’s Basilea raised a red flag about its U.S. strategy for its antibiotic ceftobiprole, noting that the FDA’s new standard requiring two late-stage studies for a program like this could present a major hurdle. Today company execs confirmed that the regulatory path into the U.S. is closed for now.

…read more

Source: FDA bars Basilea antibiotic from U.S. market, demands new PhIII data

    

0 No comments